Kevin Gade
business executiveMale0.0Global Dominance: 0.00%
Kevin Gade is the Chief Operating Officer at Bahl & Gaynor, an investment management firm. He recently gained attention for his comments on Eli Lilly's experimental weight-loss pill, orforglipron, which showed promising results in clinical trials, suggesting that the data bodes well for future trials and market prospects.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Kevin Gade is the chief operating officer at Bahl & Gaynor, which owns Lilly shares.
Eli Lilly weight-loss pill orforglipron ‘works as well as Ozempic’ in new trialThe Sydney Morning Herald·
Australia· 2025-04-17
Australia· 2025-04-17
Kevin Gade, chief operating officer at Bahl & Gaynor, stated that the data is fantastic from an efficacy standpoint.
Trial shows Eli Lilly weight-loss pill works as well as Ozempic, shares surge in responseThe Globe and Mail·
Canada· 2025-04-17
Canada· 2025-04-17
